Reversal Agents of Multidrug Resistance Mediated by Multidrug Resistance-Associated Proteins (MRPs)

ABC Transporters and Multidrug Resistance

Volumn , Issue , 2009, Pages 261-288

  Boumendjel, Ahcène ^a   Florin, Anne ^a,b   Boutonnat, Jean ^a,b  

^a UNIV GRENOBLE ALPES   (France)

^b HÔPITAL MICHALLON   (France)

Author keywords

MRP activity inhibitor evaluating methods; Multidrug resistance associated proteins and substrates or drugs extruded; Reversal agents of multidrug resistance mediated by MRPS

Indexed keywords

EID: 80255127114     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470495131.ch9     Document Type: Chapter

References (125)

1. Versantvoort CH, Broxterman HJ, Bagrij T, Scheper RJ, and Twentyman PR. 1995. Regulation by glutathione of drug transport in multidrug-resistant human lung tumour cell lines overexpressing multidrug resistance-associated protein. Br J Cancer 72: 82-89.
2. Lautier D, Canitrot Y, Deeley RG, and Cole SP. 1996. Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem Pharmacol 52: 967-977.
3. Deeley RG and Cole SP. 2006. Substrate recognition and transport by multidrug resistance protein 1 (ABCC1). FEBS Lett 580: 1103-1111.
4. Leslie EM, Deeley RG, and Cole SP. 2001. Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology 167: 3-23.
5. Yang XX, Hu ZP, Xu AL, Duan W, Zhu YZ, Huang M et al. 2006. A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor. J Pharmacol Exp Ther 319: 82-104.
6. Cui Y, Konig J, Buchholz JK, Spring H, Leier I, and Keppler D. 1999. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 55: 929-937.
7. Zelcer N, Saeki T, Reid G, Beijnen JH, and Borst P. 2001. Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem 276: 46400-46407.
8. Zeng H, Bain LJ, Belinsky MG, and Kruh GD. 1999. Expression of multidrug resistance protein-3 (multispecific organic anion transporter-D) in human embryonic kidney 293 cells confers resistance to anticancer agents. Cancer Res 59: 5964-5967.
9. Zeng H, Liu G, Rea PA, and Kruh GD. 2000. Transport of amphipathic anions by human multidrug resistance protein 3. Cancer Res 60: 4779-4784.
10. Hirohashi T, Suzuki H, Ito K, Ogawa K, Kume K, Shimizu T et al. 1998. Hepatic expression of multidrug resistance-associated protein-like proteins maintained in eisai hyperbilirubinemic rats. Mol Pharmacol 53: 1068-1075.
11. Belinsky MG, Chen ZS, Shchaveleva I, Zeng H, and Kruh GD. 2002. Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res 62: 6172-6177.
12. Kool M, van der Linden M, de Haas M, Baas F, and Borst P. 1999. Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells. Cancer Res 59: 175-182.
13. Scheffer GL, Kool M, de Haas M, de Vree JM, Pijnenborg AC, Bosman DK et al. 2002. Tissue distribution and induction of human multidrug resistant protein 3. Lab Invest 82: 193-201.
14. Hopper E, Belinsky MG, Zeng H, Tosolini A, Testa JR, and Kruh GD. 2001. Analysis of the structure and expression pattern of MRP7 (ABCC10), a new member of the MRP subfamily. Cancer Lett 162: 181-191.
15. Hopper-Borge E, Chen ZS, Shchaveleva I, Belinsky MG, and Kruh GD. 2004. Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): Resistance to docetaxel. Cancer Res 64: 4927-4930.
16. Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, and Kruh GD. 2003. Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol 63: 351-358.
17. Choudhuri S and Klaassen CD. 2006. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol 25: 231-259.
18. Dallas S, Miller DS, and Bendayan R. 2006. Multidrug resistance-associated proteins: Expression and function in the central nervous system. Pharmacol Rev 58: 140-161.
19. Kruh GD, Guo Y, Hopper-Borge E, Belinsky MG, and Chen ZS. 2007. ABCC10, ABCC11, and ABCC12. Pflugers Arch 453: 675-684.
20. Konig J, Nies AT, Cui Y, Leier I, and Keppler D. 1999. Conjugate export pumps of the multidrug resistance protein (MRP) family: Localization, substrate specificity, and MRP2-mediated drug resistance. Biochim Biophys Acta 1461: 377-394.
21. Suzuki H and Sugiyama Y. 2002. Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): Its impact on drug disposition. Adv Drug Deliv Rev 54: 1311-1331.
22. Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA et al. 1997. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homo-logues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 57: 3537-3547.
23. Lee K, Belinsky MG, Bell DW, Testa JR, and Kruh GD. 1998. Isolation of MOAT-B, a widely expressed multidrug resistance-associated protein/canalicular multispecific organic anion transporter-related transporter. Cancer Res 58: 2741-2747.
24. Chen ZS, Lee K, and Kruh GD. 2001. Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J Biol Chem 276: 33747-33754.
25. Savaraj N, Wu C, Wangpaichitr M, Kuo MT, Lampidis T, Robles C et al. 2003. Overexpression of mutated MRP4 in cisplatin resistant small cell lung cancer cell line: Collateral sensitivity to azidothymidine. Int J Oncol 23: 173-179.
26. Leggas M, Adachi M, Scheffer GL, Sun D, Wielinga P, Du G et al. 2004. Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol Cell Biol 24: 7612-7621.
27. Belinsky MG, Bain LJ, Balsara BB, Testa JR, and Kruh GD. 1998. Characterization of MOAT-C and MOAT-D, new members of the MRP/cMOAT subfamily of transporter proteins. J Natl Cancer Inst 90: 1735-1741.
28. McAleer MA, Breen MA, White NL, and Matthews N. 1999. pABC11 (also known as MOAT-C and MRP5), a member of the ABC family of proteins, has anion transporter activity but does not confer multidrug resistance when overexpressed in human embryonic kidney 293 cells. J Biol Chem 274: 23541-23548.
29. Chen ZS, Aoki S, Komatsu M, Ueda K, Sumizawa T, Furukawa T et al. 2001. Reversal of drug resistance mediated by multidrug resistance protein (MRP) 1 by dual effects of agosterol A on MRP1 function. Int J Cancer 93: 107-113.
30. Wielinga PR, van der Heijden I, Reid G, Beijnen JH, Wijnholds J, and Borst P. 2003. Characterization of the MRP4-and MRP5-mediated transport of cyclic nucleotides from intact cells. J Biol Chem 278: 17664-17671.
31. Bera TK, Lee S, Salvatore G, Lee B, and Pastan I. 2001. MRP8, a new member of ABC transporter superfamily, identified by EST database mining and gene prediction program, is highly expressed in breast cancer. Mol Med 7: 509-516.
32. Tammur J, Prades C, Arnould I, Rzhetsky A, Hutchinson A, Adachi M et al. 2001. Two new genes from the human ATP-binding cassette transporter superfamily, ABCC11 and ABCC12, tandemly duplicated on chromosome 16q12. Gene 273: 89-96.
33. Yabuuchi H, Shimizu H, Takayanagi S, and Ishikawa T. 2001. Multiple splicing variants of two new human ATP-binding cassette transporters, ABCC11 and ABCC12. Biochem Biophys Res Commun 288: 933-939.
34. Guo Y, Kotova E, Chen ZS, Lee K, Hopper-Borge E, Belinsky MG et al. 2003. MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2', 3'-dideoxycytidine and 9'-(2'-phosphonylmethoxyethyl)adenine. J Biol Chem 278: 29509-29514.
35. Chen ZS, Guo Y, Belinsky MG, Kotova E, and Kruh GD. 2005. Transport of bile acids, sulfated steroids, estradiol 17-beta-D-glucuronide, and leukotriene C4 by human multidrug resistance protein 8 (ABCC11). Mol Pharmacol 67: 545-557.
36. Bortfeld M, Rius M, Konig J, Herold-Mende C, Nies AT, and Keppler D. 2006. Human multidrug resistance protein 8 (MRP8/ABCC11), an apical efflux pump for steroid sulfates, is an axonal protein of the CNS and peripheral nervous system. Neuroscience 137: 1247-1257.
37. Bera TK, Iavarone C, Kumar V, Lee S, Lee B, and Pastan I. 2002. MRP9, an unusual truncated member of the ABC transporter superfamily, is highly expressed in breast cancer. Proc Natl Acad Sci USA 99: 6997-7002.
38. Shimizu H, Taniguchi H, Hippo Y, Hayashizaki Y, Aburatani H, and Ishikawa T. 2003. Characterization of the mouse Abcc12 gene and its transcript encoding an ATP-binding cassette transporter, an orthologue of human ABCC12. Gene 310: 17-28.
39. Pastor-Anglada M, Cano-Soldado P, Molina-Arcas M, Lostao MP, Larrayoz I, Martinez-Picado J et al. 2005. Cell entry and export of nucleoside analogues. Virus Res 107: 151-164.
40. Reid G, Wielinga P, Zelcer N, De Haas M, Van Deemter L, Wijnholds J et al. 2003. Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol 63: 1094-1103.
41. Rius M, Nies AT, Hummel-Eisenbeiss J, Jedlitschky G, and Keppler D. 2003. Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology 38: 374-384.
42. Wijnholds J, Mol CA, van Deemter L, de Haas M, Scheffer GL, Baas F et al. 2000. Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci USA 97: 7476-7481.
43. Dantzig AH, de Alwis DP, and Burgess M. 2003. Considerations in the design and development of transport inhibitors as adjuncts to drug therapy. Adv Drug Deliv Rev 55: 133-150.
44. Jedlitschky G, Burchell B, and Keppler D. 2000. The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J Biol Chem 275: 30069-30074.
45. Wu CP, Klokouzas A, Hladky SB, Ambudkar SV, and Barrand MA. 2005. Interactions of mefloquine with ABC proteins, MRP1 (ABCC1) and MRP4 (ABCC4) that are present in human red cell membranes. Biochem Pharmacol 70: 500-510.
46. Essodaigui M, Broxterman HJ, and Garnier-Suillerot A. 1998. Kinetic analysis of calcein and calcein-acetoxymethylester efflux mediated by the multidrug resistance protein and P-glycoprotein. Biochemistry 37: 2243-2250.
47. Evers R, de Haas M, Sparidans R, Beijnen J, Wielinga PR, Lankelma J et al. 2000. Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer 83: 375-383.
48. Chu XY, Strauss JR, Mariano MA, Li J, Newton DJ, Cai X et al. 2006. Characterization of mice lacking the multidrug resistance protein MRP2 (ABCC2). J Pharmacol Exp Ther 317: 579-589.
49. Sun H, Johnson DR, Finch RA, Sartorelli AC, Miller DW, and Elmquist WF. 2001. Transport of fluorescein in MDCKII-MRP1 transfected cells and mrp1-knockout mice. Biochem Biophys Res Commun 284: 863-869.
50. Xia CQ, Milton MN, and Gan LS. 2007. Evaluation of drug-transporter interactions using in vitro and in vivo models. Curr Drug Metab 8: 341-363.
51. Chang XB, Hou YX, and Riordan JR. 1997. ATPase activity of purified multidrug resistance-associated protein. J Biol Chem 272: 30962-30968.
52. Cai J, Daoud R, Alqawi O, Georges E, Pelletier J, and Gros P. 2002. Nucleotide binding and nucleotide hydrolysis properties of the ABC transporter MRP6 (ABCC6). Biochemistry 41: 8058-8067.
53. Pratt S, Chen V, Perry WI, III, Starling JJ, and Dantzig AH. 2006. Kinetic validation of the use of carboxydichlorofluorescein as a drug surrogate for MRP5-mediated transport. Eur J Pharm Sci 27: 524-532.
54. Xia CQ, Yang JJ, and Gan LS. 2005. Breast cancer resistance protein in pharmacokinetics and drug-drug interactions. Expert Opin Drug Metab Toxicol 1: 595-611.
55. Narasaki F, Oka M, Fukuda M, Nakano R, Ikeda K, Takatani H et al. 1997. A novel quinoline derivative, MS-209, overcomes drug resistance of human lung cancer cells expressing the multidrug resistance-associated protein (MRP) gene. Cancer Chemother Pharmacol 40: 425-432.
56. Robert J and Jarry C. 2003. Multidrug resistance reversal agents. J Med Chem 46: 4805-4817.
57. Aoki S, Yoshioka Y, Miyamoto Y, Higuchi K, Setiawan A, Murakami N et al. 1998. Agosterol A, a novel polyhydroxylated sterol acetate reversing multidrug resistance from a marine sponge of Spongia sp. Tetrahedron Lett 39: 6303-6306.
58. Aoki S, Setiawan A, Yoshioka Y, Higuchi K, Fudetani R, Chen ZS et al. 1999. Reversal of multidrug resistance in human carcinoma cell line by agosterols, marine spongean sterols. Tetrahedron 55: 13965-13972.
59. Murakami N, Sugimoto M, Morita M, Akiyama S, and Kobayashi M. 2000. Synthesis and evaluation of 4-deacetoxyagosterol A as an MDR-modulator. Bioorg Med Chem Lett 10: 2521-2524.
60. Murakami N, Sugimoto M, Morita M, and Kobayashi M. 2001. Total synthesis of agosterol A: An MDR-modulator from a marine sponge. Chemistry 7: 2663-2670.
61. Ren XQ, Furukawa T, Aoki S, Nakajima T, Sumizawa T, Haraguchi M et al. 2001. Glutathione-dependent binding of a photoaffinity analog of agosterol A to the C-terminal half of human multidrug resistance protein. J Biol Chem 276: 23197-23206.
62. Cole SP, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM et al. 1994. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54: 5902-5910.
63. Davey RA, Longhurst TJ, Davey MW, Belov L, Harvie RM, Hancox D et al. 1995. Drug resistance mechanisms and MRP expression in response to epirubicin treatment in a human leukaemia cell line. Leuk Res 19: 275-282.
64. Cullen KV, Davey RA, and Davey MW. 2001. Verapamil-stimulated glutathione transport by the multidrug resistance. associated protein (MRP1) in leukaemia cells. Biochem Pharmacol 62: 417-424.
65. Loe DW, Almquist KC, Deeley RG, and Cole SP. 1996. Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. J Biol Chem 271: 9675-9682.
66. Loe DW, Deeley RG, and Cole SP. 2000. Verapamil stimulates glutathione transport by the 190-kDa multidrug resistance protein 1 (MRP1). J Pharmacol Exp Ther 293: 530-538.
67. Loe DW, Oleschuk CJ, Deeley RG, and Cole SP. 2000. Structure-activity studies of verapamil analogs that modulate transport of leukotriene C(4) and reduced glutathione by multidrug resistance protein MRP1. Biochem Biophys Res Commun 275: 795-803.
68. Trompier D, Chang XB, Barattin R, du Moulinet D'Hardemare A, Di Pietro A, and Baubichon-Cortay H. 2004. Verapamil and its derivative trigger apoptosis through glutathione extrusion by multidrug resistance protein MRP1. Cancer Res 64: 4950-4956.
69. Teodori E, Dei S, Quidu P, Budriesi R, Chiarini A, Garnier-Suillerot A, Gualtieri F et al. 1999. Design, synthesis, and in vitro activity of catamphiphilic reverters of multidrug resistance: Discovery of a selective, highly efficacious chemosensitizer with potency in the nanomolar range. J Med Chem 42: 1687-1697.
70. van Zanden JJ, Geraets L, Wortelboer HM, van Bladeren PJ, Rietjens IM, and Cnubben NH. 2004. Structural requirements for the flavonoid-mediated modulation of glutathione S-transferase P1-1 and GS-X pump activity in MCF7 breast cancer cells. Biochem Pharmacol 67: 1607-1617.
71. van Zanden JJ, Wortelboer HM, Bijlsma S, Punt A, Usta M, Bladeren PJ et al. 2005. Quantitative structure activity relationship studies on the flavonoid mediated inhibition of multidrug resistance proteins 1 and 2. Biochem Pharmacol 69: 699-708.
72. Trompier D, Baubichon-Cortay H, Chang XB, Maitrejean M, Barron D, Riordon JR et al. 2003. Multiple flavonoid-binding sites within multidrug resistance protein MRP1. Cell Mol Life Sci 60: 2164-2177.
73. Nguyen H, Zhang S, and Morris ME. 2003. Effect of flavonoids on MRP1-mediated transport in Panc-1 cells. J Pharm Sci 92: 250-257.
74. Leslie EM, Deeley RG, and Cole SP. 2003. Bioflavonoid stimulation of glutathione transport by the 190-kDa multidrug resistance protein 1 (MRP1). Drug Metab Dispos 31: 11-15.
75. Miller DW, Fontain M, Kolar C, and Lawson T. 1996. The expression of multidrug resistance-associated protein (MRP) in pancreatic adenocarcinoma cell lines. Cancer Lett 107: 301-306.
76. Dantzig AH, Grese TA, Norman BH, Palkowitz AD, Sluka JP, Starling JJ et al. 1997. Benzothiphene derivatives for treating resistant tumors. Patent EP 773217, filed 11/4/1996, and issued 5/14/1997.
77. Gruber JM and Norman BH. 1999. Methods for inhibiting MRP1. Patent WO 9951227 A1, filed 4/7/1999, and issued 10/14/1999.
78. Wang S, Folkes A, Chuckowree I, Cockcroft X, Sohal S, Miller W et al. 2004. Studies on pyrrolopyrimidines as selective inhibitors of multidrug-resistance-associated protein in multidrug resistance. J Med Chem 47: 1329-1338.
79. Wang S, Wan NC, Harrison J, Miller W, Chuckowree I, Sohal S et al. 2004. Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistance. J Med Chem 47: 1339-1350.
80. Lander PA and Lohman MC. 2002. Preparation of 5-(2-pyridyl)isoxazolo[4, 3-c] quinolinones for inhibiting MRP1. Patent WO 081481, filed 3/27/2002, and issued 10/17/2002.
81. Cohen JD, Jungheim LN, Muehl BS, and Thrasher KJ. 2002. Preparation of piperidinyl-substituted isoxazolo[4, 3-c]quinolinones for inhibiting MRP1. Patent WO 081480, filed 3/27/2002, and issued 10/17/2002.
82. Bonjouklian R and York JS. 2002. Preparation of quinoline-2, 4-diones for inhibiting MRP1. Patent WO 000624, filed 6/12/2001, and issued 1/3/2002.
83. Lander PA, Wang Q, and Vepachedu S. 2001. Preparation of 5H-isoxazolo[4, 3-c] quinolin-4-ones as MRP1 inhibitors. Patent WO 096346, filed 5/31/2001, and issued 12/20/2001.
84. Bonjouklian R, Cohen JD, Gruber JM, Johnson DW, Jungheim LN, Kroin JS et al. 2001. Preparation of N-(isoxazoloquinolinylcyclohexyl)carboxamides and analogs as MRP1 inhibitors. Patent WO 046199, filed 12/11/2000, and issued 6/28/2001.
85. Bonjouklian R, Johnson DW, Lander PA, Lohman MC, Patel VF, Vepachedu S et al. 2001. Preparation of isoxazoloquinolinones as inhibitors of multidrug resistance protein 1. Patent WO 027116, filed 9/22/2000, and issued 4/19/2001.
86. Norman BH, Gruber JM, Hollinshead SP, Wilson JW, Starling JJ, Law KL et al. 2002. Tricyclic isoxazoles are novel inhibitors of the multidrug resistance protein (MRP1). Bioorg Med Chem Lett 12: 883-886.
87. Mao Q, Qiu W, Weigl KE, Lander PA, Tabas LB, Shepard RL et al. 2002. GSH-dependent photolabeling of multidrug resistance protein MRP1 (ABCC1) by [1251]LY475776. Evidence of a major binding site in the COOH-proximal membrane spanning domain. J Biol Chem 277: 28690-28699.
88. Wang S, Ryder H, Pretswell I, Depledge P, Milton J, Hancox TC et al. 2002. Studies on quinazolinones as dual inhibitors of Pgp and MRP1 in multidrug resistance. Bioorg Med Chem Lett 12: 571-574.
89. Burg D, Filippov DV, Hermanns R, van der Marel GA, van Boom JH, and Mulder GJ. 2002. Peptidomimetic glutathione analogues as novel gammaGT stable GST inhibitors. Bioorg Med Chem 10: 195-205.
90. Tew KD, Bomber AM, and Hoffman SJ. 1988. Ethacrynic acid and piriprost as enhancers of cytotoxicity in drug resistant and sensitive cell lines. Cancer Res 48: 3622-3625.
91. Hansson J, Berhane K, Castro VM, Jungnelius U, Mannervik B, and Ringborg U. 1991. Sensitization of human melanoma cells to the cytotoxic effect of melphalan by the glutathione transferase inhibitor ethacrynic acid. Cancer Res 51: 94-98.
92. Ford JM, Hait WN, Matlin SA, and Benz CC. 1991. Modulation of resistance to alkylating agents in cancer cell by gossypol enantiomers. Cancer Lett 56: 85-94.
93. Sauna ZE, Peng XH, Nandigama K, Tekle S, and Ambudkar SV. 2004. The molecular basis of the action of disulfiram as a modulator of the multidrug resistance-linked ATP binding cassette transporters MDR1 (ABCB1) and MRP1 (ABCC1). Mol Pharmacol 65: 675-684.
94. O'Brien ML, Vulevic B, Freer S, Boyd J, Shen H, and Tew KD. 1999. Glutathione peptidomimetic drug modulator of multidrug resistance-associated protein. J Pharmacol Exp Ther 291: 1348-1355.
95. Flatgaard JE, Bauer KE, and Kauvar LM. 1993. Isozyme specificity of novel glutathione-S-transferase inhibitors. Cancer Chemother Pharmacol 33: 63-70.
96. Morgan AS, Ciaccio PJ, Tew KD, and Kauvar LM. 1996. Isozyme-specific glutathione S-transferase inhibitors potentiate drug sensitivity in cultured human tumor cell lines. Cancer Chemother Pharmacol 37: 363-370.
97. Leslie EM, Bowers RJ, Deeley RG, and Cole SP. 2003. Structural requirements for functional interaction of glutathione tripeptide analogs with the human multidrug resistance protein 1 (MRP1). J Pharmacol Exp Ther 304: 643-653.
98. Burg D and Mulder GJ. 2002. Glutathione conjugates and their synthetic derivatives as inhibitors of glutathione-dependent enzymes involved in cancer and drug resistance. Drug Metab Rev 34: 821-863.
99. Awasthi S, Srivastava SK, Ahmad F, Ahmad H, and Ansari GA. 1993. Interactions of glutathione S-transferase-pi with ethacrynic acid and its glutathione conjugate. Biochim Biophys Acta 1164: 173-178.
100. Ploemen JH, van Ommen B, and van Bladeren PJ. 1990. Inhibition of rat and human glutathione S-transferase isoenzymes by ethacrynic acid and its glutathione conjugate. Biochem Pharmacol 40: 1631-1635.
101. Burg D, Wielinga P, Zelcer N, Saeki T, Mulder GJ, and Borst P. 2002. Inhibition of the multidrug resistance protein 1 (MRP1) by peptidomimetic glutathione-conjugate analogs. Mol Pharmacol 62: 1160-1166.
102. Burg D, Hameetman L, Filippov DV, van der Marel GA, and Mulder GJ. 2002. Inhibition of glutathione S-transferase in rat hepatocytes by a glycine-tetrazole modified S-alkyl-GSH analogue. Bioorg Med Chem Lett 12: 1579-1582.
103. Ogino J, Moore RE, Patterson GM, and Smith CD. 1996. Dendroamides, new cyclic hexapeptides from a blue-green alga. Multidrug-resistance reversing activity of dendroamide A. J Nat Prod 59: 581-586.
104. Xia Z and Smith CD. 2001. Total synthesis of dendroamide A, a novel cyclic peptide that reverses multiple drug resistance. J Org Chem 66: 3459-3466.
105. Abad-Merin MJ, Cortes N, Masip I, Perez-Paya E, Ferragut JA, Messeguer A et al. 2005. Trimers of N-alkylglycines are potent modulators of the multidrug resistance phenotype. J Pharmacol Exp Ther 313: 112-120.
106. Meister A. 1988. Glutathione metabolism and its selective modification. J Biol Chem 263: 17205-17208.
107. Lather V and Madan AK. 2005. Topological model for the prediction of MRP1 inhibitory activity of pyrrolopyrimidines and templates derived from pyrrolopy-rimidine. Bioorg Med Chem Lett 15: 4967-4972.
108. Chang G and Roth CB. 2001. Structure of MsbA from E. coli: A homolog of the multidrug resistance ATP binding cassette (ABC) transporters. Science 293: 1793-1800.
109. Locher KP, Lee AT, and Rees DC. 2002. The E. coli BtuCD structure: A framework for ABC transporter architecture and mechanism. Science 296: 1091-1098.
110. Sauna ZE, Smith MM, Muller M, Kerr KM, and Ambudkar SV. 2001. The mechanism of action of multidrug-resistance-linked P-glycoprotein. JBioenergBiomembr 33: 481-491.
111. Manciu L, Chang X, Riordan JR, Buyse F, and Ruysschaert JM. 2001. Nucleotide-induced conformational changes in the human multidrug resistance protein MRP1 are related to the capacity of chemotherapeutic drugs to accumulate or not in resistant cells. FEBS Lett 493: 31-35.
112. Manciu L, Chang XB, Buyse F, Hou YX, Gustot A, Riordan JR, and Ruysschaert JM. 2003. Intermediate structural states involved in MRP1-mediated drug transport. Role of glutathione. J Biol Chem 278: 3347-3356.
113. Borst P, Evers R, Kool M, and Wijnholds J. 1999. The multidrug resistance protein family. Biochim Biophys Acta 1461: 347-357.
114. Daoud R, Julien M, Gros P, and Georges E. 2001. Major photoaffinity drug binding sites in multidrug resistance protein 1 (MRP1) are within transmembrane domains 10-11 and 16-17. J Biol Chem 276: 12324-12330.
115. Karwatsky JM and Georges E. 2004. Drug binding domains of MRP1 (ABCC1) as revealed by photoaffinity labeling. Curr Med Chem Anticancer Agents 4: 19-30.
116. Wortelboer HM, Usta M, van Zanden JJ, van Bladeren PJ, Rietjens IM, and Cnubben NH. 2005. Inhibition of multidrug resistance proteins MRP1 and MRP2 by a series of alpha, beta-unsaturated carbonyl compounds. Biochem Pharmacol 69: 1879-1890.
117. Weiss J, Theile D, Ketabi-Kiyanvash N, Lindenmaier H, and Haefeli WE. 2007. Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. Drug Metab Dispos 35: 340-344.
118. Asakura E, Nakayama H, Sugie M, Zhao YL, Nadai M, Kitaichi K et al. 2004. Azithromycin reverses anticancer drug resistance and modifies hepatobiliary excretion of doxorubicin in rats. Eur J Pharmacol 484: 333-339.
119. Patel NJ, Zamek-Gliszczynski MJ, Zhang P, Han YH, Jansen PL, Meier PJ et al. 2003. Phenobarbital alters hepatic Mrp2 function by direct and indirect interactions. Mol Pharmacol 64: 154-159.
120. Payen L, Delugin L, Courtois A, Trinquart Y, Guillouzo A, and Fardel O. 2001. The sulphonylurea glibenclamide inhibits multidrug resistance protein (MRP1) activity in human lung cancer cells. Br J Pharmacol 132: 778-784.
121. Bodo A, Bakos E, Szeri F, Varadi A, and Sarkadi B. 2003. Differential modulation of the human liver conjugate transporters MRP2 and MRP3 by bile acids and organic anions. J Biol Chem 278: 23529-23537.
122. Naramoto H, Uematsu T, Uchihashi T, Doto R, Matsuura T, and Usui Y. 2007. Multidrug resistance-associated protein 7 expression is involved in crossresistance to docetaxel in salivary gland adenocarcinoma cell lines. Int J Oncol 30: 393-401.
123. Tan TM, Yang F, Fu H, Raghavendra MS, and Lam Y. 2007. Traceless solid-phase synthesis and biological evaluation of purine analogs as inhibitors of multidrug resistance protein 4. J Comb Chem 9: 210-218.
124. Kowalski P, Surowiak P, and Lage H. 2005. Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2, and BCRP. Mol Ther 11: 508-522.
125. Folmer Y, Schneider M, Blum HE, and Hafkemeyer P. 2007. Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-ABCC2 antisense constructs. Cancer Gene Ther 14: 875-884.